Denali Therapeutics Inc.’s brain-penetrating enzyme replacement therapy DNL310 (ETV:IDS) has shown beneficial clinical effects in children with Hunter syndrome (MPS II), in interim data from a Phase I/II study, although the performance of a new potential biomarker for the condition apparently disappointed some investors.
The South San Francisco, CA-based firm said it was excited about the results emerging from the study, which continue to...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)